Targeted Therapy Response Can Predict Survival in HCC, Findings Suggest
Patients with previously untreated liver cancer, or hepatocellular carcinoma (HCC), lived twice as long if they responded to a tyrosine kinase inhibitor, a type of targeted therapy.
BY Wayne Kuznar
PUBLISHED March 19, 2019
Patients with previously untreated liver cancer, or hepatocellular carcinoma (HCC), lived twice as long if they responded to a tyrosine kinase inhibitor, a type of targeted therapy, compared with patients for whom the drug had little benefit, according to an analysis of results from a randomized clinical trial.
Responders to Lenvima (lenvatinib) or Nexavar (sorafenib) lived a median of 22.4 months versus 11.4 months for patients who did not achieve either a partial or complete response. The analysis considered a variety of factors that could have affected overall survival and identified response to treatment as a way to predict this outcome.
“The association between objective response and overall survival was consistent with results reported in previous studies,” said Masatoshi Kudo, M.D., of Kindai University Faculty of Medicine in Osaka, Japan. “Therefore, patients who achieve an objective response can potentially expect a longer overall survival.” Objective response refers to the proportion of patients who experienced a prespecified amount of tumor shrinkage lasting at least a certain amount of time.
Additional studies are needed to validate the association between objective response and survival, Kudo added.
The data analyzed came from the phase 3 REFLECT trial, which compared Lenvima and Nexavar in patients with previously untreated HCC and found that Lenvima was more effective. An analysis of response at two, four and six months showed a significant survival advantage, ranging from five to seven months, for patients who responded to treatment.